Drug Pricing: Page 4
-
Sponsored by GoodRx
Worried about provider consolidation? Learn about GoodRx engagement solutions
GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.
Oct. 10, 2022 -
ALS drug development
Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost
The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog believes to be reasonable, given its purported benefit.
By Jacob Bell • Sept. 30, 2022 -
Trendline
Drug pricing
Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.
By BioPharma Dive staff -
Novartis warns of sales hit after federal court turns back patent appeal
The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.
By Kristin Jensen • Sept. 21, 2022 -
Deep Dive
Can biosimilars, after years of limited impact, finally make a mark in the US?
Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.
By Jonathan Gardner • Sept. 7, 2022 -
Q&A
Akili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment
With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.
By Elise Reuter • Aug. 29, 2022 -
With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.
By Jacob Bell • Aug. 25, 2022 -
With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
Approved for severe beta thalassemia, Zynteglo will test insurers’ willingness to pay for expensive one-time treatments. Its market launch is likely to be watched carefully by other gene therapy developers.
By Ned Pagliarulo • Aug. 18, 2022 -
Pharma industry braces as drug pricing bill passes Congress
The Inflation Reduction Act, signed into law by President Biden in August, was one of the most significant political defeats for the industry in years, and will reshape companies’ business plans moving forward.
By Christopher Newman • Aug. 15, 2022 -
Senate passage of drug pricing bill brings major defeat closer for pharma industry
The legislation, which would allow Medicare to negotiate prices on up to 60 drugs by 2029, passed on a party-line vote and now goes to the House, where it is expected to pass.
By Christopher Newman • Aug. 8, 2022 -
Pharma CEOs press case against drug price negotiation as bill gains support
On earnings calls with investors, executives reiterated opposition to legislation advanced by Democrats that would curtail their pricing power in the U.S.
By Christopher Newman • Aug. 4, 2022 -
Roche digs deeper into gene therapy for the eye
The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments.
By Jonathan Gardner • July 20, 2022 -
UnitedHealth to offer some drugs, including insulin, at no cost share in 2023
The initiative aims to address inflationary pressures and prevent worse health outcomes down the line, CEO Andrew Witty told investors Friday.
By Rebecca Pifer • July 15, 2022 -
California to manufacture its own insulin, governor says
Gov. Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”
By Susan Kelly • July 11, 2022 -
Watchdog group cautious on Amylyx’s ALS drug benefits, potential cost
ICER, an influential nonprofit, suggested in a draft report that Amylyx’s closely watched ALS treatment would not be cost effective if priced on par with a currently available treatment.
By Ned Pagliarulo • Updated June 14, 2022 -
Roche SMA drug approved in youngest infants, challenging Novartis and Biogen
Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.
By Jonathan Gardner • May 31, 2022 -
Medicare premiums to remain unchanged after Aduhelm price cut spurs review
HHS Secretary Becerra had sought to cut premiums for seniors sooner, but "legal and operational hurdles" prevented a change mid-year, the department said in a Friday statement.
By Samantha Liss • May 31, 2022 -
Drug price hikes moderate as rebates rise, report finds
List prices for branded medicines rose by nearly 5% last year, according to IQVIA, a figure that fell to 1% after accounting for rebates and discounts.
By Ned Pagliarulo • April 21, 2022 -
Hospitals mark up cancer drug prices for private insurance patients, study shows
Researchers also found U.S. spending on cancer medicines rose from about $39 billion in 2015 to nearly $68 billion in 2019 largely due to manufacturer and hospital market power.
By Hailey Mensik • April 19, 2022 -
UK bid to battle antibiotic resistance yields first subscription-style plan
Pfizer and Shionogi could receive 10 million pounds, or about $13 million, a year for new antibiotics. International participation might be needed to further spur development, however.
By Jonathan Gardner • April 12, 2022 -
Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug
Biogen said it is considering its options following CMS' decision, which restricts reimbursement of Aduhelm to patients enrolled in a randomized clinical trial.
By Jonathan Gardner • Updated April 7, 2022 -
Civica targets insulin in effort to produce cheaper drugs
The nonprofit group announced ambitious plans to begin offering insulin at prices no higher than $30 per vial by early 2024.
By Kristin Jensen • March 3, 2022 -
Biden discusses drug prices, mental health services in annual address
The president also announced a "test-to-treat" program that would allow people to receive free antiviral pills, such as Pfizer's Paxlovid or Merck's molnupiravir, after a COVID-19 test at a pharmacy.
By Shannon Muchmore • March 2, 2022 -
FTC deadlocks on vote to launch study into PBM practices
The antitrust agency won't study pharmacy benefit managers' pricing and contract practices as proposed, after a 2-2 vote by commissioners Thursday.
By Samantha Liss • Feb. 17, 2022 -
Lilly's new COVID-19 antibody becomes US' latest tool to battle omicron
The speedy clearance of Lilly’s bebtelovimab comes after the U.S. stopped distributing two of the company's earlier antibodies because they couldn't effectively neutralize the variant.
By Jonathan Gardner • Updated Feb. 11, 2022 -
FDA sends signal with tough questions of Lilly at cancer drug meeting
The agency criticized Eli Lilly for using a trial run in China to seek approval of an immunotherapy it licensed from Innovent Biologics. Outside advisers agreed in a decisive vote that could have repercussions for several other drugmakers.
By Jonathan Gardner • Feb. 10, 2022